Short-Term PPIs Tied to Higher Hip Fracture Risk in Alzheimer's

Share this content:
Short-Term PPIs Tied to Higher Hip Fracture Risk in Alzheimer's
Short-Term PPIs Tied to Higher Hip Fracture Risk in Alzheimer's

THURSDAY, March 22, 2018 (HealthDay News) -- Short-term proton pump inhibitor use, but not long-term or cumulative use, is associated with an increased risk of hip fracture among Alzheimer's patients, according to a study published online March 6 in Alimentary Pharmacology and Therapeutics.

Sanna Torvinen-Kiiskinen, from the University of Eastern Finland in Kuopio, and colleagues used national data from the Finnish MEDALZ dataset to identify 4,818 community-dwelling individuals with Alzheimer's disease who experienced incident hip fracture (mean age, 84.1 years). There were 19,235 controls matched with the cases at the date of hip fracture.

The researchers found that long-term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture. However, there was an increased risk associated with current proton pump inhibitor use (adjusted odds ratio [OR], 1.12). The risk was also increased with short-term current use of (less than one year; adjusted OR, 1.23).

"Our findings do not support previous assumptions that long-term proton pump inhibitor use would be associated with an increased risk of hip fractures," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Increase Seen in Salmonella Illnesses From Ground Beef

CDC: Increase Seen in <i>Salmonella</i> Illnesses From Ground ...

246 people now sickened; 59 people have been hospitalized; no deaths reported to date

Epinephrine Personal Autoinjectors Cost-Effective at 24

Epinephrine Personal Autoinjectors Cost-Effective at &#36;24

Based on 10-fold fatality risk difference, value-based price for personal epinephrine $24

Burden of Liver Cancer Rising in Medicare Patients

Burden of Liver Cancer Rising in Medicare Patients

Coexistence of other liver conditions tied to even higher risk for death, health care costs

is free, fast, and customized just for you!




Already a member?

Sign In Now »